adminThis series of six, one-hour webinars, developed by the Pennsylvania Medical Society (PAMED), is designed to help educate physicians and other health care providers on the appropriate use of long-acting and extended- release opioids.
These webinars are approved for CME, open to all prescribers in Pennsylvania, and cover prescribing, monitoring, assessment, and documentation. Click on the links below to view the webinar. To obtain CME credit, click on the appropriate attestation statement below after you have viewed all six webinars.
| Topic/Presenter |
Additional Resources |
| Interdisciplinary Pain Care: Where Do Opioids Fit In? Michael Ashburn, MD, MPH, MBA Perry Fine, MD |
|
| Chronic Opioid Therapy for Non-Cancer Pain: Does It Work and at What Cost? Roger Chou, MD, MPH Martin Cheatle, PhD |
|
| Patient Assessment and Initial Opioid Dosing for Opioid Therapy for Non-Cancer Pain Russell Bell, MD Martin Cheatle, PhD |
|
| Patient Monitoring During Ongoing Treatment Michael Ashburn, MD, MPH, MBA Roger Chou, MD, MPH |
|
| When and How to Discontinue Chronic Opioid Therapy Martin Cheatle, PhD Russell Bell, MD |
|
| Risk Management and Documentation Perry Fine, MD Michael Ashburn, MD, MPH, MBA |
| I attest that I’ve completed the required educational components of this activity and am ready to complete the CME assessment. Physicians who watch the six webinar series and successfully complete the assessment will earn 6.00 AMA PRA Category 1 Credits™. | |||
I am a physician and want to claim my completer certificate and CME credit
|
I am not a physician and want to claim my completer certificate and access to CME
|
||
This CME activity is available at no cost to physicians and non physician health care team providers.
Although physician training on this topic is not yet federally mandated, some federal agencies would like it to be required. According to a recent FDA consumer bulletin those agencies are working to get Congress to link mandatory physician training to the already required FDA registration number that physicians must have to prescribe controlled substances.
Last fall, PAMED launched its “Pills for Ills, Not Thrills” campaign designed to raise awareness of problems associated with pill-seeking doctor shoppers—patients that hop from physician to physician looking to score prescription pain medication for illegal use. These educational webinars are the next step in that campaign.
Accreditation statement
The Pennsylvania Medical Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Designation statement
The Pennsylvania Medical Society designates these enduring materials for a maximum of 6.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.Acknowledgement:
Presented by the Pennsylvania Medical Society, a cooperating member of the Collaborative on REMS Education (CO*RE) interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.RPC Commercial Support Disclosure Statement:
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies (RPC). Please see www.er-la-opioidREMS.com for a listing
of the member companies.This activity is intended to be fully-compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration (FDA).
Activity Development Team
- Michael Ashburn, MD, MPH, MBA (Faculty/Planning)
GW Pharma, Medtronic, Teva, Insys, Maruishi (2012-13)- Russell Bell, MD (Faculty/Planning)
Nothing to disclose- Roger Chou, MD (Faculty/Planning)
Nothing to disclose- Martin Cheatle, PhD (Faculty/Planning)
Ameritox, Inc. – honoraria, Endo Pharm – honoraria- Perry Fine, MD (Faculty/Planning)
Takeda – advisory board, Pfizer and Nektar –speaker/educ program,
ISA Scientific – Board of Directors, Asante Communications – 5% equity partner- Leslie Howell (Planning)
Nothing to disclose- Diane Seibert (Planning)
Nothing to discloseExpiration date – 12/31/16